Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 14/20 | 0.67 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1873230 | 0.92 | SSTR5 (0.66) | SSTR5HRH1HTR2BMCHR1APP | |
| SCHEMBL1882159 | 0.91 | SSTR5 (0.61) | SSTR5HRH1HTR2BMCHR1APP | |
| SCHEMBL1877815 | 0.90 | SSTR5 (0.65) | SSTR5HRH1HTR2BMCHR1APP | |
| SCHEMBL1870840 | 0.89 | KDM4E (0.59) | SSTR5HRH1HTR2BMCHR1ACHE | |
| SCHEMBL1878808 | 0.88 | SSTR5 (0.53) | SSTR5HRH1HTR2BMCHR1APP | |
| SCHEMBL1881707 | 0.88 | SSTR5 (0.67) | SSTR5HRH1HTR2BMCHR1APP | |
| SCHEMBL1874053 | 0.87 | SSTR5 (0.53) | SSTR5HRH1HTR2BMCHR1APP | |
| SCHEMBL1880245 | 0.87 | SSTR5 (0.54) | SSTR5HRH1HTR2BMCHR1APP | |
| SCHEMBL1879972 | 0.87 | SSTR5 (0.66) | SSTR5HRH1HTR2BMCHR1APP | |
| SCHEMBL1875550 | 0.85 | SSTR5 (0.60) | SSTR5HRH1HTR2BMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939661-B2 | Antidiabetic agents; somatostatin receptor subtype 5 modulators; noninsulin dependent diabetes mellitus; side effect reduction; synthesis | HOFFMAN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | claimed |
| US-20080064697-A1 | PYRIDINE, QUINOLINE AND PYRIMIDINE DERIVATIVES | HOFFMAN-LA ROCHE INC. | 2008-03-13 | — | — | US | claimed |
| US-7939661-B2 | Antidiabetic agents; somatostatin receptor subtype 5 modulators; noninsulin dependent diabetes mellitus; side effect reduction; synthesis | HOFFMAN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | disclosed |
| EP-2066658-A1 | PYRIDINE- AND QUINOLINE-PYRIMIDINE-DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008031735-A1 | PYRIDINE- AND QUINOLINE-PYRIMIDINE-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-20 | — | — | WO | disclosed |
| US-20080064697-A1 | PYRIDINE, QUINOLINE AND PYRIMIDINE DERIVATIVES | HOFFMAN-LA ROCHE INC. | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064697-A1 | PYRIDINE, QUINOLINE AND PYRIMIDINE DERIVATIVES | SSTR5, SSTR3, NPY5R | SSTR5 1/4885HRH1 97/4885HTR2B 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.